Description

BSE received clarifications from Emcure Pharmaceuticals Ltd and Landmark Global Learning Ltd regarding significant increase in volume/price movement of their securities, both companies stating the movement is market-driven with no undisclosed material information.

Summary

BSE’s Surveillance Department sought clarifications from two listed companies — Emcure Pharmaceuticals Ltd (Scrip Code: 544210) and Landmark Global Learning Ltd (Scrip Code: 544341) — regarding significant increases in the volume/price of their respective securities. Both companies responded on March 10, 2026, stating that the movement is purely market-driven and that there is no material event or information required to be disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Points

  • Emcure Pharmaceuticals Ltd responded to BSE surveillance email ref. no. L/SURV/ONL/PV/APJ/2025-2026/961, confirming no undisclosed material event exists.
  • Landmark Global Learning Ltd (formerly Landmark Immigration Consultants Limited) responded to BSE surveillance email ref. no. L/ISURV/ONL/PV/SJ/2025-20/234614 dated March 9, 2026.
  • Both companies affirmed that price/volume increases are market-driven and outside the companies’ control.
  • Both companies confirmed compliance with Regulation 30 of SEBI LODR Regulations and committed to timely future disclosures.
  • Emcure’s response was signed by Company Secretary & Compliance Officer Amruta Yangalwar (Membership No. A25687).

Regulatory Changes

No regulatory changes. These are standard surveillance clarification responses under the existing SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 framework.

Compliance Requirements

  • Companies are required to respond to BSE surveillance queries in a timely manner.
  • Listed entities must comply with Regulation 30 of SEBI LODR Regulations for disclosure of material events/information.
  • Both companies have confirmed ongoing adherence to disclosure obligations.

Important Dates

  • March 9, 2026: BSE surveillance query issued to Landmark Global Learning Ltd.
  • March 10, 2026: BSE surveillance query issued to Emcure Pharmaceuticals Ltd.
  • March 10, 2026: Both companies submitted their clarification responses to BSE.

Impact Assessment

Minimal market or operational impact. These are routine surveillance clarifications with no adverse findings. No trading restrictions, penalties, or regulatory actions have been indicated. Investors should note that both companies have confirmed no pending material disclosures, which may provide reassurance regarding compliance posture. The volume/price movements remain unexplained by any corporate event.

Impact Justification

Routine clarification responses from companies under BSE surveillance query; no material undisclosed information, no regulatory action, and no changes to trading or compliance requirements.